Pattern of TGFbeta receptor 1 expression differs between kras-mutated keratoacanthomas and squamous cell carcinomas of the skin

Pathology Research and Practice

Volumn 210, Issue 9, 2014, Pages 596-602

  Berger, Franziska ^a   Geddert, Helene ^a   Faller, Gerhard ^a   Werner, Martin ^b   Dimmler, Arno ^a  

^a St Vincentius Hospital   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

EGFR; Keratoacanthoma; Skin carcinogenesis; Squamous cell carcinoma; TGFbeta

Indexed keywords

SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; BRAF GENE; EGFR GENE; EPIDERMIS; EXON; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; PATHOGENESIS; PHENOTYPE; PYROSEQUENCING; SKIN CARCINOMA; SMAD2 GENE; SMAD3 GENE; SUN EXPOSURE; TGFBETA1 GENE; TGFBETAR2 GENE; TUMOR DIFFERENTIATION; AGED; CARCINOMA, SQUAMOUS CELL; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; MALE; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS;

AGED; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MALE; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS;

EID: 84926409689     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.05.006     Document Type: Article

References (40)

1. Groves R.W., Allen M.H., MacDonald D.M. Abnormal expression of epidermal growth factor receptor in cutaneous epithelial tumours. J. Cutan. Pathol. 1992, 19:66-72.
2. Bulj T.K., Krunic A.L., Cetner A.S., Villano J.L. Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib. Br. J. Dermatol. 2010, 163:633-637.
3. Reid D.C., Guitart J., Agulnik M., Lacouture M.E. Treatment of multiple keratoacanthomas with erlotinib. Int. J. Clin. Oncol. 2010, 15:413-415.
4. Stagno F., Vigneri P., Del Fabro V., Stella S., Restuccia N., Giallongo C., Massimino M., Berretta S., Pennisi M.S., Tibullo D., Tirro E., Buscarino C., Messina A., Di Raimondo F. Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias. Acta Oncol. 2010, 49:109-110.
5. Maubec E., Petrow P., Scheer-Senyarich I., Duvillard P., Lacroix L., Gelly J., Certain A., Duval X., Crickx B., Buffard V., Basset-Seguin N., Saez P., Duval-Modeste A.B., Adamski H., Mansard S., Grange F., Dompmartin A., Faivre S., Mentre F., Avril M.F. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J. Clin. Oncol. 2011, 29:3419-3426.
6. Sok J.C., Coppelli F.M., Thomas S.M., Lango M.N., Xi S., Hunt J.L., Freilino M.L., Graner M.W., Wikstrand C.J., Bigner D.D., Gooding W.E., Furnari F.B., Grandis J.R. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 2006, 12:5064-5073.
7. Schwentner I., Witsch-Baumgartner M., Sprinzl G.M., Krugmann J., Tzankov A., Jank S., Zwierzina H., Loeffler-Ragg J. Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head Neck 2008, 30:1040-1044.
8. Mauerer A., Herschberger E., Dietmaier W., Landthaler M., Hafner C. Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort. Exp. Dermatol. 2011, 20:848-850.
9. Uribe P., Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol. Res. Pract. 2011, 207:337-342.
10. Corominas M., Sloan S.R., Leon J., Kamino H., Newcomb E.W.A. Pellicer, ras activation in human tumors and in animal model systems. Environ. Health Perspect. 1991, 93:19-25.
11. Su F., Viros A., Milagre C., Trunzer K., Bollag G., Spleiss O., Reis-Filho J.S., Kong X., Koya R.C., Flaherty K.T., Chapman P.B., Kim M.J., Hayward R., Martin M., Yang H., Wang Q., Hilton H., Hang J.S., Noe J., Lambros M., Geyer F., Dhomen N., Niculescu-Duvaz I., Zambon A., Niculescu-Duvaz D., Preece N., Robert L., Otte N.J., Mok S., Kee D., Ma Y., Zhang C., Habets G., Burton E.A., Wong B., Nguyen H., Kockx M., Andries L., Lestini B., Nolop K.B., Lee R.J., Joe A.K., Troy J.L., Gonzalez R., Hutson T.E., Puzanov I., Chmielowski B., Springer C.J., McArthur G.A., Sosman J.A., Lo R.S., Ribas A., Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 2012, 366.:207-215.
12. Harradine K.A., Ridd K., Saunier E.F., Clermont F.F., Perez-Losada J., Moore D.H., Epstein E.H., Bastian B.C., Akhurst R.J. Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin. Cancer Res. 2009, 15:5101-5107.
13. Goudie D.R., D'Alessandro M., Merriman B., Lee H., Szeverenyi I., Avery S., O'Connor B.D., Nelson S.F., Coats S.E., Stewart A., Christie L., Pichert G., Friedel J., Hayes I., Burrows N., Whittaker S., Gerdes A.M., Broesby-Olsen S., Ferguson-Smith M.A., Verma C., Lunny D.P., Reversade B., Lane E.B. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat. Genet. 2011, 43:365-369.
14. Ackerman A.B. Differential Diagnosis in Dermatopathology 1982, Lea & Febiger, Philadelphia, PA.
15. Bacman D., Merkel S., Croner R., Papadopoulos T., Brueckl W., Dimmler A. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 2007, 7:156.
16. Han G., Lu S.L., Li A.G., He W., Corless C.L., Kulesz-Martin M., Wang X.J. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J. Clin. Invest. 2005, 115:1714-1723.
17. Lu S.L., Reh D., Li A.G., Woods J., Corless C.L., Kulesz-Martin M., Wang X.J. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004, 64:4405-4410.
18. Reiss M. TGF-beta and cancer. Microbes Infect. 1999, 1:1327-1347.
19. Gold L.I. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit. Rev. Oncog. 1999, 10:303-360.
20. Padua D., Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009, 19:89-102.
21. Li A.G., Lu S.L., Han G., Kulesz-Martin M., Wang X.J. Current view of the role of transforming growth factor beta 1 in skin carcinogenesis. J. Investig. Dermatol. Symp. Proc. 2005, 10:110-117.
22. Quan T., He T., Kang S., Voorhees J.J., Fisher G.J. Ultraviolet irradiation alters transforming growth factor beta/smad pathway in human skin in vivo. J. Invest. Dermatol. 2002, 119:499-506.
23. Han K.H., Choi H.R., Won C.H., Chung J.H., Cho K.H., Eun H.C., Kim K.H. Alteration of the TGF-beta/SMAD pathway in intrinsically and UV-induced skin aging. Mech. Ageing Dev. 2005, 126:560-567.
24. Hoot K.E., Lighthall J., Han G., Lu S.L., Li A., Ju W., Kulesz-Martin M., Bottinger E., Wang X.J. Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J. Clin. Invest. 2008, 118:2722-2732.
25. Arnault J.P., Mateus C., Escudier B., Tomasic G., Wechsler J., Hollville E., Soria J.C., Malka D., Sarasin A., Larcher M., Andre J., Kamsu-Kom N., Boussemart L., Lacroix L., Spatz A., Eggermont A.M., Druillennec S., Vagner S., Eychene A., Dumaz N., Robert C. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin. Cancer Res. 2012, 18:263-272.
26. Hodak E., Jones R.E., Ackerman A.B. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am. J. Dermatopathol. 1993, 15:332-342. discussion 343-352.
27. Dimmler A., Kiesewetter F., Liehr T., Neubauer S., Schell H., Gebhart E. Interphase-FISH examinations in paraffin sections from benign, precancerous, and cancerous lesions of the skin and oral mucosa. Int. J. Oncol. 1997, 10:83-88.
28. Li J., Wang K., Gao F., Jensen T.D., Li S.T., Deangelis P.M., Kolvraa S., Proby C., Forslund O., Bolund L., Clausen O.P. Array comparative genomic hybridization of keratoacanthomas and squamous cell carcinomas: different patterns of genetic aberrations suggest two distinct entities. J. Invest. Dermatol. 2012, 132:2060-2066.
29. Corbalan-Velez R., Martinez-Barba E., Lopez-Poveda M.J., Vidal-Abarca Gutierrez I., Ruiz-Macia J.A., Oviedo-Ramirez I., Martinez-Menchon T. The value of laminin-322 staining in distinguishing between keratoacanthoma, keratoacanthoma with areas of squamous cell carcinoma, and crateriform squamous cell carcinoma. Actas Dermosifiliogr. 2012, 103:308-316.
30. Fujii M., Honma M., Takahashi H., Ishida-Yamamoto A., Iizuka H. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma. Clin. Exp. Dermatol. 2011, 36:788-792.
31. Cabibi D., Aragona F., Guarnotta C., Rodolico V., Zerilli M., Belmonte B., Schillaci L., Aragona F. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients. Appl. Immunohistochem. Mol. Morphol. 2011, 19:239-245.
32. Vasiljevic N., Andersson K., Bjelkenkrantz K., Kjellstrom C., Mansson H., Nilsson E., Landberg G., Dillner J., Forslund O. The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma. Int. J. Cancer 2009, 124:2361-2366.
33. Tan K.B., Lee Y.S. Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: differences in pattern and correlation with pathobiology. Histopathology 2009, 55:338-345.
34. Tataroglu C., Karabacak T., Apa D.D. Beta-catenin and CD44 expression in keratoacanthoma and squamous cell carcinoma of the skin. Tumori 2007, 93:284-289.
35. Slater M., Barden J.A. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 2005, 47:170-178.
36. Basta-Juzbasic A., Klenkar S., Jakic-Razumovic J., Pasic A., Loncaric D. Cytokeratin 10 and Ki-67 nuclear marker expression in keratoacanthoma and squamous cell carcinoma. Acta Dermatovenerol. Croat. 2004, 12:251-256.
37. Papadavid E., Pignatelli M., Zakynthinos S., Krausz T., Chu A.C. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma. Br. J. Dermatol. 2001, 145:582-589.
38. Ho T., Horn T., Finzi E. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch. Dermatol. 1991, 127:1167-1171.
39. Kannon G., Park H.K. Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma. Am. J. Dermatopathol. 1990, 12:31-36.
40. Ariano M.C., Wiley E.L., Ariano L., Coon J.S.t., Tetzlaff L. H, peanut lectin receptor, and carcinoembryonic antigen distribution in keratoacanthomas, squamous dysplasias, and carcinomas of skin. J. Dermatol. Surg. Oncol. 1985, 11:1076-1083.